One of the largest newspapers in Switzerland, the Neue Zurcher Zeitung (NZZ), called the Russian-made coronavirus vaccine Sputnik V an export hit, RIA Novosti reported.
We are talking about an article dedicated to the low rate of vaccination in Russia against the background of high demand for the drug abroad.
“The demand for the vaccine is strong around the world, especially after the vaccine was 92 percent effective,” writes NZZ. Further it is said about RDIF data, according to which the Russian drug is superior to the products of Biontech / Pfizer and Moderna
Earlier on February 24, it became known that the Russian vaccine was tested in Japan. Tests have shown an efficiency of over 94 percent.
The Russian drug “Sputnik V” was developed by the Gamaleya Research Center for Electrochemistry and became the world's first registered vaccine based on the human adenovirus. Currently, the development of Russian scientists is among the ten best vaccine candidates in the list of the World Health Organization (WHO). In Russia, the vaccination campaign started on December 5, 2020. Later, the Russian Ministry of Health registered another drug – EpiVacCorona, developed by the Vector Center of Rospotrebnadzor.
